Cerebroprotein Hydrolysate
CPH, cerebroprotein hydrolysate injection, 'Cerebrolysin' (mislabelled by some vendors)
Cerebroprotein Hydrolysate (CPH, cerebroprotein hydrolysate injection, 'Cerebrolysin' (mislabelled by some vendors)) is a cognitive & mood research compound. A porcine brain-derived peptide preparation: brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposed action is neurotrophic — the peptide fraction is claimed to mimic the effect of endogenous neurotrophic factors such as BDNF, GDNF and NGF, which are themselves far too large to cross the blood-brain barrier. Small peptides that survive digestion are the proposed messengers.
Cerebroprotein Hydrolysate quick facts
| Reported research dose | 30mg per vial (vendor format); clinical CPH courses run 10-60mg/day |
| Route | IM or slow IV in clinical use |
| Frequency | 1x Daily · Daily during a course |
| Half-life | Not well characterised |
| Forms | Injectable |
| Evidence level | Chinese and Indian clinical studies in stroke and cognitive impairment; not the same trial base as Cerebrolysin |
**Read this before assuming it is Cerebrolysin.** It is a closely related idea from a different manufacturer with a different evidence base, and several research vendors label it 'Cerebrolysin' because the two are cousins. The tell is the format: **Cerebrolysin is a liquid ampoule concentrate and is never sold as a lyophilised 30mg powder.** If you are buying a 30mg lyophilised vial, you are buying cerebroprotein hydrolysate. That distinction matters for dosing. Cerebrolysin is dosed in millilitres of a standardised concentrate; CPH is dosed in milligrams of powder. Carrying a Cerebrolysin protocol across to a CPH vial is not a conversion anyone can do reliably, because the peptide profiles are not the same. See the Cerebrolysin card for the product with the larger, better-replicated trial base.
How Cerebroprotein Hydrolysate works
A porcine brain-derived peptide preparation: brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposed action is neurotrophic — the peptide fraction is claimed to mimic the effect of endogenous neurotrophic factors such as BDNF, GDNF and NGF, which are themselves far too large to cross the blood-brain barrier. Small peptides that survive digestion are the proposed messengers.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
✅ Clinically validated
- Randomised trials exist, largely from China and India, in acute stroke, traumatic brain injury and vascular cognitive impairment, generally reporting modest improvement on cognitive scales against standard care. This is a separate evidence base from Cerebrolysin's — different manufacturers, different preparations, and the two are routinely conflated in marketing because the products are cousins.
- Quality is mixed: many trials are small, single-centre, open-label, and published in journals that Western reviewers do not commonly index. That is a reason for caution about effect size, not proof of absence.
📊 Correlative data
- Used clinically in several Asian markets as an IM or slow-IV course, typically 10-20 days. Practitioner reports centre on cognition and recovery after neurological insult rather than on enhancement in healthy people, which is the population most research buyers belong to and the one nobody has studied.
🧪 Theoretical / extrapolated
- Porcine brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposal is that these fragments act as neurotrophic mimetics — standing in for BDNF, GDNF and NGF, which are far too large to cross the blood-brain barrier.
- The format is how you tell it apart from Cerebrolysin, and it matters for dosing. Cerebrolysin is a standardised LIQUID ampoule concentrate dosed in millilitres; cerebroprotein hydrolysate is a LYOPHILISED powder dosed in milligrams. Several research vendors list a 30mg lyophilised vial under the name 'Cerebrolysin' — that product is this one. A protocol written for one cannot be converted to the other, because the peptide profiles are not the same and neither is standardised against the other.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Cerebroprotein Hydrolysate — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalising: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterised. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get Cerebroprotein Hydrolysate
See vetted vendors for Cerebroprotein Hydrolysate →Cerebroprotein Hydrolysate — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Cerebroprotein Hydrolysate moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Cerebroprotein Hydrolysate — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
Get the complete breakdown for Cerebroprotein Hydrolysate — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside Cerebroprotein Hydrolysate
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anaemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 102 markers A–Z
Cerebroprotein Hydrolysate — frequently asked questions
What is Cerebroprotein Hydrolysate?
Cerebroprotein Hydrolysate (CPH, cerebroprotein hydrolysate injection, 'Cerebrolysin' (mislabelled by some vendors)) is a cognitive & mood research compound. A porcine brain-derived peptide preparation: brain tissue is enzymatically digested and filtered to leave low-molecular-weight peptides and free amino acids. The proposed action is neurotrophic — the peptide fraction is claimed to mimic the effect of endogenous neurotrophic factors such as BDNF, GDNF and NGF, which are themselves far too large to cross the blood-brain barrier. Small peptides that survive digestion are the proposed messengers.
Is the full Cerebroprotein Hydrolysate protocol on this page?
The reported research dose is on this page, along with how Cerebroprotein Hydrolysate works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of Cerebroprotein Hydrolysate?
Cerebroprotein Hydrolysate has an approximate half-life of Not well characterised, which is part of what determines how often it's dosed.
What's the evidence behind Cerebroprotein Hydrolysate?
Current evidence level: Chinese and Indian clinical studies in stroke and cognitive impairment; not the same trial base as Cerebrolysin. Cerebroprotein Hydrolysate is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact Cerebroprotein Hydrolysate protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →